Dr. Christopher R. Antolini, MD
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Medical school
- West Virginia University School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 296
Licensed in Colorado since 2008, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: West Virginia University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
CO license 0046724 (first issued 2008; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- HCA Healthone Rose Denver, CO
Medical groups
- Select Physical Therapy of West Denver Limited PArtnership (548 clinicians)
- Denver Arthritis Clinic PC (13 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 296
- Services billed
- 59,182
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 7,525 | 20 |
| Injection, golimumab, 1 mg, for intravenous use | 5,750 | 11 |
| Injection, denosumab, 1 mg | 5,400 | 62 |
| Injection, infliximab, excludes biosimilar, 10 mg | 3,830 | 15 |
| Established patient office or other outpatient visit, 30-39 minutes | 381 | 193 |
| Administration of chemotherapy into vein, 1 hour or less | 286 | 70 |
| Infusion, normal saline solution, 250 cc | 193 | 53 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 176 | 80 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 150 | 18 |
| Insertion of needle into vein for collection of blood sample | 139 | 59 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Denver, CO | 304 |
| Hydroxychloroquine Sulfate Other prescribers in Denver, CO | 192 |
| Methotrexate (methotrexate sodium) Other prescribers in Denver, CO | 164 |
| Tramadol Hcl Other prescribers in Denver, CO | 164 |
| Allopurinol Other prescribers in Denver, CO | 81 |
| Celecoxib Other prescribers in Denver, CO | 79 |
| Gabapentin Other prescribers in Denver, CO | 77 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Denver, CO | 60 |
| Meloxicam Other prescribers in Denver, CO | 54 |
| Folic Acid Other prescribers in Denver, CO | 46 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 29 payments worth $528 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $204 |
|---|---|
| Amgen Inc. | $69.28 |
| AbbVie Inc. | $68.96 |
| AstraZeneca Pharmaceuticals LP | $64.94 |
| GlaxoSmithKline, LLC. | $51.07 |
| Genzyme Corporation | $32.36 |
| Genentech USA, Inc. | $21.00 |
| E.r. Squibb & Sons, L.l.c. | $15.96 |
| Food and Beverage | $528 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 9 companies. The companies reported $3,512,814 in research payments for these studies, mostly to the institutions running them.
- A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants
Amgen Inc. - ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)?
Janssen Research & Development, LLC - A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic…
Takeda Pharmaceuticals U.S.A., Inc. - A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1)
E.r. Squibb & Sons, L.l.c. - Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588296 - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity
Amgen Inc. - A Multicenter Randomized Double blind Placebo controlled Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus and Refractory and/or In…
AstraZeneca UK Limited - M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
AbbVie Inc. - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
AbbVie Inc. · Active, not recruiting · NCT03671148 - A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.